NCT02414646 (Clinical Trial/ Ado-Trastuzumab Emtansine)

Study Title
Trastuzumab Emtansine in Treating Older Patients With Human Epidermal Growth Factor Receptor 2-Positive Stage I-III Breast Cancer (NCT02414646)

Trial Description
This phase II trial studies how well ado-trastuzumab emtansine (T-DM1, Kadcyla®; Genentech, Inc.) works in treating older patients with human epidermal growth factor receptor 2 (HER2)-positive stage I-III breast cancer. HER2 is a protein found on the surface of cancer cells that helps them to grow and spread. Trastuzumab emtansine may kill cancer cells by binding to HER2-positive on the surface of the tumor cells and blocking their ability grow and spread.

This trial is sponsored by Academic and Community Cancer Research United (ACCRU)/ National Cancer Institute (NCI). [1]

Study Data

  • Condition:
    • Estrogen Receptor Negative
    • HER2 Positive Breast Carcinoma
    • Progesterone Receptor Negative
    • Stage IB Breast Cancer
    • Stage IIA Breast Cancer
    • Stage IIB Breast Cancer
    • Stage IIIA Breast Cancer
    • Stage IIIC Breast Cancer
  • Interventions:
    • Drugs used in this trial
    • Other: Questionnaire Administration
    • Other: Laboratory Biomarker Analysis
    • Other: Quality-of-Life Assessment
  • Phase: II
  • Estimated Enrollment: 200
  • Start: May 2015
  • Estimated Primary Completion: June 2020
  • Last verified: July 2015

Study Schematic

(Coming soon)

Click here to Return to Drug map


Last Editorial review: July 28, 2015
Information based on ClinicalTrials.gov (NIH/NCI) and other sources.

Copyright © 2015 InPress Media Group. All rights reserved. Republication or redistribution of InPress Media Group content, including by framing or similar means, is expressly prohibited without the prior written consent of InPress Media Group. InPress Media Group shall not be liable for any errors or delays in the content, or for any actions taken in reliance thereon. ADC Review / Journal of Antibody-drug Conjugates is a registered trademarks and trademarks of InPress Media Group around the world.

Add to Flipboard Magazine.